Stuart, thank morning. joining you for this all Thanks and us
Let pandemic Passage me begin other by remarking we despite at accomplishments on of and the XXXX in COVID-XX faced all last the we critical challenges year year. Bio had
is that We position began CNS view grounded in for strong raised successful financial year, as XXXX. in to successful life foundational We XXX offering a a with transition clinical in position year we a which mission transforming with a We XXXX the with disorders. strengthened from work company IPO, in company's therapies to us our this Our which build. which devastating to earlier gave on patients develop proceeds. public focused million net a further XXXX for stage preparing financial
and are gangliosidosis, with dementia of this over advancing PBKRXX half PBGMXX programs first focused PBFTXX US, Canada. development frontotemporal past for three granulin all begin GMX recently We regulatory mutations. clearance and which the Our in disease UK year for work clinical the Krabbe on of to the in year, received set for
for applications and Krabbe Other pediatric recent of granulin patient currently dementia in note designation. disease the frontotemporal both the site continue XXXX. clinical I/II activated dose by regulatory GMX Agency disease, for FDA US mutations. In Krabbe for European actions adoption our expect and Phase orphan disease for drug PBGMOX for patients. to the we designations the FDA with patients positive treatment with global early received in Krabbe and Other programs progress, of from early for are programs, first of additional to and IND rare site study Medicines and the XXXX, Imagine-X orphan clearance we recruiting the are in first our first quarter infantile also our a infantile for drug PBKRXX the GMX. activations also of in two to take opinion an For We've
European endorse the the to quarter. end the of positive Commission opinion by expect We the
to granted medical the and FDA need. recently, development to expedite facilitate drugs program treat of Just FTD and our serious designation designed review the is conditions unmet which Track Fast fill
Our also expanding strides FDA. gene advancing from are engagement drug and important We've programs. also crucial earlier designation orphan our made received to FTD successful which program this identification therapy efforts patient year
identify For GMX History Center, ScreenPlus ongoing and from patients who as Disease to early Orphan Penn's collaborations addition we Invitae able may our with the program, therapies. to help New York our in as Natural benefit our be investigational Study possible, with to have
We FTD screening are for Natural are trial while in sponsoring which may Studies, identify History participating and engaging that helpful genetic GENFI also FTD enrollment also the to counseling in be FTD for with clinical patients patients sites our and ongoing study. ALL
to own pipeline, advance control our to testing of as this establishing with provide manufacturing supply late will our of end-to-end last our global flexibility Catalent will CGMP and across product and development, These validation. initiation year in analytical the together includes in are needs our of we second as growing plant side, our dedicated CMC quarter manufacturing the growing external with us clinical partnerships, This at lab the suite our capabilities clinical assay supply increased chain opening and and support internal meet the chain. pipeline. year, vector us of enable On manufacturing to well
in partnership planned a as our continuing we goal all from The outset, have disorders. patients to the and part well to strength, each to our strong operate on remarks programs program I Wilson XXXX clinical support our XXXX, capabilities delivered stage, clinical of with financial three portion from we will continue initiatives, beyond our that updating pipeline and identification and advancement the experienced the at three in said rare Jim well manufacturing development programs able spend large you as most been operations. I position through Passage position advancing to initiatives progresses programs. progressing of continue expand various pipeline to priority be Penn. because our As therapy to advancing strong my advanced development, CNS continued patient to extremely shared We and earlier supporting between with team. financial collaboration engagement these next as of anticipate internal of gene our of programs and the productive our a advancement In as Bio, to at Bio's demonstrates and clinical of our and our the pipeline Passage will bolstering
our with for Imagine-X start Let's study GMX. infantile
extremely first I we clinical assay to mentioned, regulatory into As received have be development. are moving excited our clearance and
a beta-galactosidase. a rare is caused impacts monogenic GMX disease As enzyme is GLBX that in encoding storage recessive patients the by the gene lysosomal devastating reminder, mutations worldwide. It
the Human current through generation which the a and form PBGMOX GTP from to treatment very We the with utilizes GMX. intra-cisterna Published next administered Therapy is journal the no disease tissues. brain AAVhuXX also care. preclinical severe most PBGMOX disease, and course options rapid in to magna data of peer peripheral capsid a are beyond supports a treatment deliver the beta-gal supportive encoding reviewed the infantile functional the the for as to Gene GLBX gene potential targeting
cisterna four each open for two a with dose is Phase early will labeled of a dose a I/II escalation in enroll infantile onset magna by The of and administered PBGMOX global onset separate into trial the Imagine-X patients injection late total GMX. Our infantile GMX. early study with infantile onset of and cohorts cohorts late subjects escalation study single
site activated and this mentioned patient I our to expect first earlier, quarter. we in As dose have first our
also XX-day in beta-gal mid-XXXX. our to initial We safety activity impact from initial enzyme biomarker specifically and cohort data, on expect the report
screening globally eligible have and the authorizations We for open and We patients trial and currently sites. to underway clinical are US, the XX are trial plan sites for actively Canada. additional UK activations in
agencies a in both and We effect. a and GMX to due are key Turkey, founder's in physicians there's of countries discussion with incidence regulatory also which higher in Brazil
patient medical newborn genetic leading to sites, clinical are continue on York we a efforts. their we rare well which company, education pilot offers up and diseases. This Invitae, as bring identification wrapping testing as ScreenPlus As partnership screening for the with program, our New of includes sponsorship
driving the coordinator site with are that study investigators strong forward. we the Additionally, have relationships
half of in of to safety to Turning Phase we or both I/II year FTD-GRN, for We and initial to anticipate occur with were start receive and data trials the continuing. early are readouts IND from disease Krabbe late trials very first the preparations biomarker for the in in both FDA programs happy XXXX XX-day this clearance XXXX.
reach for outside US around filings indications, we trial in patients we as authorizations are and for countries As clinical filing the provide those expand our appropriate. regulatory seek we'll to updates the globe these to on further also two
age. or programs mutations give and early enzyme will Krabbe being brief Krabbe leads treatment lysosomal and Krabbe or peripheral to starting by I the results disease galactosylceramidase encoding untreated, Leukodystrophy GALC. This years to overview the developed Next, disease caused brain in of you cells. next the storage disease DNA a of rapid mortality damage for capsid AAVhuXX Globoid by FTD-GRN utilizes with the patient's PBKROX disease. a generation infantile to for enzyme galactosylceramidase of is rare gene progressive two encoding to system both a in nervous Cell and PBKRXX if deliver
an PBKROX Krabbe will the Our cisterna in escalation a pediatric single be injection disease. administered by with study into infantile trial early subjects Phase open I/II dose magna label of
demonstrate that Krabbe the disease. is of study infantile for goal is first early Our safe with to patients PBKROX
increase escalation spinal in and dosage separated patients. this group. of is program biomarker second the trial for the of by We similar will in design both the age very serum hope goal an cerebral portion our by and increase The dose to to Our look to GMX demonstrate in GALC. demonstrate fluid
with a will escalation enrolling cohorts, four at subjects of separate based We three of be dose enrollment. total age on cohorts each
low deemed with dose will the subjects dosing of age. are between initiate dose low a move cohort in we who in nine high age, will of tolerable, four into one cohort if four of subjects and who subjects are and and age who first dose months and a and safe PBKROX are months cohort the of also four months in between nine of We between
planned subjects The first to initial cohort Our age final will data expansion will cohort is four These cohorts escalation and both months groups. for confirmatory be age. data. high dose dose include a dose the and safety in XX-day followed from cohort by evaluate escalation a one readout of between biomarker
diseases, on rare early all I've identification main impacts and As with when such patient programs, working other the discussed of considering and is leading especially and this, initiatives the physicians we're To patient point, is groups as for Krabbe. expand devastating with screening. to newborn disease a case focus support a
The granulin impact adults generally can Turning in causing X,XXX progranulin's FTD our uncertain, in only the FTD PBFTOX an a causes XX% similar is of of as increasing attention is of years onset, the a of at X,XXX XXs. this common midlife young Alzheimer's which FTD to in of results patients progression of an lysosomal executive patients adult dementia, occurs to function. in by their because after to FTD affecting The of one FTD, behavior, disease evidence impairment patients eight causing occurs for language But mutations gene, progranulin. onset X% early deficiency most in United than old. In rapid individuals the disease States, survival role condition or frequency average the in which XX symptoms. and approximately XXs. is deficiency points years progranulin of to results younger with function as GRN mechanism in to but in and
progranulin Annals reminder, of protein. study a The vector single PBFTOX via by of label in optimized levels to granulin into therapy administration FTD-GRN. is in demonstrated FTD of GTP, preclinical will Translational peer Clinical pathogenic more the published utilizes progranulin mutations study. In GRN by journal be of an our gene As the PDFTOX reviewed vector the single a I/II a magna deliver that scientific AAVX open advancement brain, Neurology, and a subjects PBFTOX Phase an of gene clinical a AAVX functional encoding CSF symptomatic escalation program to the a progranulin study XX-fold and than or dose supporting injection the early of reaching administered cisterna with into in PBFTOX gene the
Phase I/II goals have We for study. the key two
for safe Our is that PBFTOX first is demonstrate with patients to FTD-GRN. goal
Our second goal levels is to demonstrate in the CSF. increased progranulin
optional dosing patients enroll an in cohort, two a PBFTOX will three will first the dose We cohorts and of with cohort. low with initiate third of each
As in we the from initial typical if data cohort. a and readout tolerated, for study study, the levels. biomarker CSF safety well escalation is will XX-day change cohort second The first dose from a the low dose is and data progranulin will baseline higher dose data, including include
As impacts our geographies. to worldwide. with serving is and programs patients dedicated we charge. genetic potential And are support the devastating and We've help have of the groups FTD to in to disease are working continued with patient relationships and to of reach across counseling build patients patients discussed, to FTD that a US we increase screening free
while have address we the services and measures development implemented months. the travel clinical to such party for maintaining support patients the providing very challenges to have clinical vendors patient clearance of will safety three excited possible, patients regulatory We dosing lead rigor as three and believe and our coming these to look of therapies with assessments To as we all also remote top approaches associated these our our potentially is our the burdens facilitate programs, all altering Again, programs COVID-XX, to and priority. where to life ability patients. current increase we are trials, third concierge through to provide on provide in our embark received begin restrictions. we updates further forward of As
an establishing of I both launching company of differentiated and tenant securing internal our been progress year our control the mentioned manufacturing our as Turning Manufacturing external approach chain since key advance and pipeline. capabilities. our important capacity to to this is has we grow as towards important our made have manufacturing, of we a strategy part earlier, continue and supply
of laboratories & initiated Therapy Hopewell, and Innovation the in which include CGMP in vector need. clinical in support we and agreements global well second our facility clinical on validation; distribution testing a as Jersey, These New as to open based a at Gene development to signed global production product will supply XXXX and flexible quarter number for manufacturing on of the at Some suite partnerships Cell entering from a chain into for span Princeton established accomplishments supply lease by West in Maryland; assay our recent dedicated demand sites clinical clinical manufacturing analytical Catalent our to plan and our end-to-end vectors plasma and agreements. packaging patient Campus the which
Phase We are place. pleased Imagine-X with partnership through to already share that in is our clinical supply trial for Catalent PBGMOX I/II for our manufactured
We have manufactured FTD-GRN. study next and Krabbe programs for of to for clinical most supplies two of for disease advanced also our clinical initiation our support
And programs give superb continuing turn with the expertise. invested call want key update. to transformational trial our and we and to to we in processes to clinical leader manufacturing be goal we're a our to Finally, I to end-to-end substantially that, XXXX, Rich internal financial delivering patients. manufacturing note over the expand therapies R&D In XXXX, to in that hire a with gene of ensure to our talent will execution
